Venture capital fund · 1 deal
Investment management for sophisticated investors
Sydney, NSW
Every published round Gannet Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Gannet Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Azura Ophthalmics | 23 Oct 2020 | 1 | 0 |
Fund closes reported for Gannet Capital, as distinct from the investments it has made.
Companies Gannet Capital has backed that another company then bought. An exit for the holding, not a deal Gannet Capital did.
| Name | Role | Sources |
|---|---|---|
| Glenn Poswell | Founder & Principal | Startup Daily, Gannet Capital team page |
Stories naming Gannet Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Nakatomi, an Australian startup studio, has collected $3.5 million from backers including Scalare Partners and Leonardo.AI's Chris Gillis, cash it will deploy creating several companies each year.
ASX-listed venture fund Touch Ventures is parting with chief executive Hein Vogel; the piece recalls its 2021 $100 million listing, heavy write-offs on PlanPay and Till Payments, and Basiq's sale to Cuscal.
Brandon Capital's blog republishes an AFR report on Azura Ophthalmics' encouraging phase 2 dry-eye results, recalling the Israel-founded biotech's US$38 million raised, among it a US$16 million round that Brandon Capital's fund co-led.
Azura Ophthalmics reports positive phase two results for its dry eye ointment and moves toward registration studies; the Brandon Capital-backed biotech has raised US$38 million, including a US$16 million round co-led by MRCF.
Eye-disease drug developer Azura Ophthalmics announced a $28 million round from existing backers including MRCF, OrbiMed, TPG Biotech and Ganot Capital, funding registration studies of its dry eye treatment candidate.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio